Human FCRL2/FcRH2 , FCRL5/FcRH5 Alexa Fluor® 350-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB2048U
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Glu15-Asp395
Accession # Q96LA5
Specificity
Clonality
Host
Isotype
Applications
Flow Cytometry
Sample: Human peripheral blood monocytes
Formulation, Preparation, and Storage
Purification
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: FCRL2/FcRH2
Fc receptor-like 2 (FCRL2), also known as FcRH2 and IRTA4, belongs to the family of glycoprotein homologs of classical immunoglobulin (Ig) Fc receptors. In human, the type I transmembrane FCRL protein family contains from three to nine immunoglobulin-like domains (1, 2). Mature human FcRH2 consists of a 382 amino acid (aa) extracellular domain (ECD) with four Ig-like C2-set domains, a 21 aa transmembrane segment, and an 86 aa cytoplasmic domain with one ITAM-like, and two ITIM-like motifs (3‑5). Alternate splicing of human FCRL2 may generate isoforms with N-terminal, internal, or C-terminal deletions (4, 5). The gene for FcRH2 maps to the human Iq21-23 locus which is a hotspot for chromosomal translocation events associated with B cell malignancies (3, 6). Although there are several Fc receptor-like genes in the mouse, none of these is a clear ortholog to human FCRL2 (7). FCRL proteins are differentially expressed among B cells (2). FCRL2 is preferentially expressed on naïve and CD27+ memory B cells within the spleen, lymph nodes, tonsils, and peripheral blood (3, 4, 8, 9). It is also expressed on most B cells in B cell chronic lymphocytic leukemia (B-CLL) patients (10). FCRL2 upregulation is associated with mutation of the immunoglobulin heavy chain variable (IGHV) and less aggressive forms of B-CLL (9, 11).
References
- Maltais, L.J. et al. (2006) Nat. Immunol. 7:431.
- Davis, R.S. et al. (2007) Annu. Rev. Immunol. 25:525.
- Miller, I. et al. (2002) Blood 99:2662.
- Davis, R.S. et al. (2001) Proc. Natl. Acad. Sci. 98:9772.
- Xu, M.J. et al. (2001) Biochem. Biophys. Res. Commun. 280:768.
- Hatzivassiliou, G. et al. (2001) Immunity 14:277.
- Davis, R.S. et al. (2004) Int. Immunol. 16:1343.
- Polson, A.G. et al. (2006) Int. Immunol. 18:1363.
- Huttmann, A. et al. (2006) Leukemia 20:1774.
- Kazemi, T. et al. (2008) Int. J. Cancer 123:2113.
- Li, F.J. et al. (2008) Blood 112:179.
Long Name
Alternate Names
Entrez Gene IDs
Gene Symbol
UniProt
Additional FCRL2/FcRH2 Products
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
For research use only